Solifenacin Orion
Anticholinergic 5 mg Tablet for Overactive Bladder Symptoms
Quick Facts About Solifenacin Orion
Key Takeaways About Solifenacin Orion
- Effective for overactive bladder: Solifenacin 5 mg significantly reduces urinary urgency, frequency, and incontinence episodes in clinical trials, with measurable improvement typically seen within 1–4 weeks
- Once-daily convenience: A long elimination half-life (45–68 hours) allows a single daily tablet, with or without food, providing consistent 24-hour bladder control
- Dry mouth is the most common side effect: Anticholinergic effects such as dry mouth, constipation, and blurred vision are usually mild and often diminish with continued use
- Not for everyone: Solifenacin Orion is contraindicated in patients with urinary retention, uncontrolled narrow-angle glaucoma, severe gastrointestinal conditions, myasthenia gravis, and those undergoing haemodialysis
- Drug interactions require attention: Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) can significantly increase solifenacin levels; patients on these medications should remain on the 5 mg dose
What Is Solifenacin Orion and What Is It Used For?
Solifenacin Orion contains the active substance solifenacin succinate, which belongs to a class of medications called anticholinergics (antimuscarinics). It is used to treat the symptoms of overactive bladder (OAB), including a sudden, strong need to urinate (urgency), needing to urinate more often than usual (frequency), and involuntary urine leakage when you cannot reach the toilet in time (urge incontinence).
Overactive bladder is a highly prevalent condition affecting an estimated 12–17% of the adult population worldwide, according to the International Continence Society (ICS). Its prevalence rises with age and can affect both men and women, although the underlying pathophysiology may differ between sexes. The condition occurs when the detrusor muscle in the bladder wall contracts involuntarily, causing sudden and often uncontrollable urges to urinate that may occur day and night. While OAB is not a life-threatening condition, it can substantially impair quality of life, affecting work, sleep, social activities, intimate relationships, and emotional well-being. Many patients also limit their fluid intake or avoid leaving home to manage symptoms – coping strategies that can themselves cause additional health problems.
Solifenacin works by selectively blocking muscarinic M3 receptors, which are the predominant type of muscarinic receptor found on the detrusor muscle of the bladder. By blocking the action of the neurotransmitter acetylcholine at these receptors, solifenacin reduces the frequency and intensity of involuntary detrusor contractions during the bladder filling phase. In practical terms, this means that patients can wait longer before needing to use the toilet, the bladder can hold a larger volume of urine before a sense of urgency develops, and episodes of urgency and incontinence occur less often. Importantly, solifenacin does not prevent the normal contraction of the bladder during voluntary voiding when the detrusor must contract to empty the bladder.
Compared with some older anticholinergic medications used for OAB (such as oxybutynin), solifenacin demonstrates a more favourable receptor selectivity profile. It has a greater affinity for M3 receptors than for M2 receptors and a relatively low affinity for muscarinic receptors in other organs, such as the salivary glands and the central nervous system. This selectivity contributes to a better balance between efficacy and tolerability. Nevertheless, anticholinergic side effects (particularly dry mouth, constipation, and blurred vision) remain the most common adverse reactions because these receptors are also present elsewhere in the body.
Landmark clinical trials (most notably the STAR, VENUS, and VIOLET studies) have demonstrated that solifenacin 5 mg once daily significantly reduces the number of urgency episodes, micturitions per 24 hours, and incontinence episodes compared with placebo. The medication is equally effective in men and women, and its benefits are sustained during long-term use of 12 months or more. Solifenacin is included in the World Health Organization (WHO) Model List of Essential Medicines and is recommended as a first-line pharmacological treatment for OAB in the European Association of Urology (EAU) and American Urological Association (AUA) guidelines.
Solifenacin Orion is a generic version of solifenacin, marketed by Orion Corporation. As a generic medicinal product, it has been approved by regulatory authorities on the basis of proven bioequivalence to the originator product, meaning that it releases the same amount of active substance into the bloodstream at the same rate. The 5 mg strength of Solifenacin Orion is the standard starting dose for adults with OAB and is effective for most patients. Note that unlike some other solifenacin products on the market, Solifenacin Orion is only available in the 5 mg strength.
Solifenacin was first approved by the European Medicines Agency (EMA) in 2004 under the originator brand name Vesicare (developed by Astellas Pharma). Following patent expiry, several generic manufacturers – including Orion Corporation, Accord Healthcare, Sandoz, and Krka – have introduced generic solifenacin products. All approved generics contain the same active substance (solifenacin succinate) in equivalent amounts and are therapeutically interchangeable.
About the Manufacturer
Orion Corporation is a Finnish pharmaceutical company headquartered in Espoo, Finland, with a history dating back to 1917. Orion develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company has a substantial portfolio of both innovative and generic products, with a particular presence in central and northern European markets. Solifenacin Orion is part of the company's generic portfolio, produced under strict European Union Good Manufacturing Practice (GMP) standards.
What Should You Know Before Taking Solifenacin Orion?
Before starting Solifenacin Orion, inform your doctor about all your medical conditions, particularly any bladder obstruction, gastrointestinal disorders, kidney or liver problems, and glaucoma. Solifenacin has several important contraindications and requires caution in specific patient groups.
As with any prescription medication, Solifenacin Orion should only be used after a thorough medical assessment. Your doctor will consider your medical history, current medications, and any symptoms you are experiencing to determine whether solifenacin is suitable for you. A careful review of existing conditions is especially important because the anticholinergic action of solifenacin can worsen certain pre-existing problems and may be dangerous in specific clinical scenarios. Open and honest discussion with your healthcare provider is the foundation of safe and effective treatment.
Contraindications
You must not take Solifenacin Orion if any of the following apply to you:
- Allergy to solifenacin succinate or any of the other ingredients in the tablet – allergic reactions may include skin rash, itching, swelling, or difficulty breathing
- Urinary retention – difficulty urinating or inability to completely empty the bladder, as solifenacin could worsen this condition by further relaxing the bladder muscle
- Severe gastrointestinal conditions – including toxic megacolon (a serious complication of ulcerative colitis) or other severe gastric or intestinal diseases, because anticholinergics reduce gut motility
- Myasthenia gravis – a neuromuscular disease causing extreme muscle weakness, as anticholinergics may worsen symptoms
- Uncontrolled narrow-angle glaucoma – increased intraocular pressure with progressive loss of vision, as anticholinergics can further raise eye pressure
- Haemodialysis – patients undergoing kidney dialysis should not use this medication
- Severe liver impairment – as solifenacin is extensively metabolised in the liver
- Severe renal impairment or moderate hepatic impairment combined with treatment with a strong CYP3A4 inhibitor (e.g., ketoconazole) – this combination can lead to dangerously high drug levels
Tell your doctor if you have any of the conditions listed above before starting treatment with Solifenacin Orion. Using this medication when contraindicated can lead to serious complications, including acute urinary retention, intestinal obstruction, or a dangerous increase in intraocular pressure. When in doubt, always ask your doctor or pharmacist before taking your first dose.
Warnings and Precautions
Talk to your doctor or pharmacist before taking Solifenacin Orion if you have or have had any of the following conditions:
- Bladder outflow obstruction – difficulty emptying the bladder or a weak urinary stream, as solifenacin may increase the risk of urinary retention (particularly relevant in men with benign prostatic hyperplasia)
- Gastrointestinal obstructive disorders – including chronic constipation, as anticholinergics can slow bowel movements further
- Risk of decreased gastrointestinal motility – your doctor will have informed you if this applies to you
- Severe renal impairment – the maximum recommended dose is 5 mg daily, which corresponds to the single available strength of Solifenacin Orion
- Moderate hepatic impairment – the maximum recommended dose is 5 mg daily
- Hiatus hernia or gastro-oesophageal reflux disease – anticholinergics may worsen reflux symptoms
- Autonomic neuropathy – a condition affecting the involuntary nervous system
- Known QT prolongation or treatment with other QT-prolonging medicines – solifenacin has been associated with QT prolongation in some patients
Before starting treatment, your doctor should investigate whether there are other reasons for your frequent urination, such as heart failure, kidney disease, diabetes mellitus, or a urinary tract infection. If a urinary tract infection is present, your doctor will prescribe an appropriate antibiotic before starting solifenacin, because treating the infection alone may resolve the urinary symptoms. In older patients, a post-void residual volume measurement may be performed to exclude significant bladder outflow obstruction before anticholinergic therapy is initiated.
Angioedema (sudden swelling of the face, lips, throat, or tongue) with airway obstruction has been reported in some patients taking solifenacin. If this occurs, stop taking Solifenacin Orion immediately and seek emergency medical attention. Angioedema can become life-threatening if it obstructs breathing.
Use in Children and Adolescents
Solifenacin Orion is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of solifenacin in this age group have not been established in the adult indication of OAB, and paediatric patients with bladder symptoms should be managed by a specialist paediatric urologist with experience in childhood urological conditions. Paediatric patients with neurogenic detrusor overactivity are typically managed with other formulations or non-pharmacological approaches.
Pregnancy and Breastfeeding
You should not use Solifenacin Orion if you are pregnant unless your doctor has determined that it is absolutely necessary. The potential effects of solifenacin on human pregnancy have not been adequately studied, and as a precautionary measure, this medication should be avoided during pregnancy. Animal studies have not indicated a direct harmful effect with respect to fertility or embryonal/foetal development, but human data remain limited. If you discover that you are pregnant while taking Solifenacin Orion, contact your doctor immediately to discuss alternative management strategies.
Solifenacin should not be used during breastfeeding. No data are available on the excretion of solifenacin into human breast milk, but the active substance was excreted into the milk of mice. If treatment for overactive bladder is required during breastfeeding, your doctor will discuss whether to discontinue breastfeeding or to use an alternative treatment approach, such as behavioural therapy, pelvic floor muscle training, or a medicinal product with a better-documented lactation safety profile.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and Operating Machinery
Solifenacin Orion can cause blurred vision and, less commonly, drowsiness or fatigue. If you experience any of these effects, you should not drive a vehicle or operate heavy machinery until the symptoms have resolved. These side effects are most likely to occur at the start of treatment or in the first few weeks of therapy, and they may be more pronounced if you are also taking other central nervous system depressants or multiple anticholinergic medications. You are personally responsible for assessing whether you are fit to drive or perform tasks that require alertness, visual acuity, or rapid reaction times.
Important Information About Excipients
Solifenacin Orion tablets contain lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, meaning it is essentially sodium-free and suitable for patients on a sodium-controlled diet.
How Does Solifenacin Orion Interact with Other Drugs?
Solifenacin Orion can interact with several medications, including other anticholinergics, CYP3A4 inhibitors (such as ketoconazole and ritonavir), CYP3A4 inducers (such as rifampicin and carbamazepine), and prokinetic agents. Always inform your doctor about all medications, supplements, and herbal products you are taking.
Solifenacin is primarily metabolised by the liver enzyme cytochrome P450 3A4 (CYP3A4). Medications that affect this enzyme system can significantly alter solifenacin blood levels – either increasing them (and the risk of side effects) or decreasing them (and the clinical effectiveness). Additionally, because solifenacin has anticholinergic properties, combining it with other anticholinergic drugs can lead to additive side effects, while combining it with cholinergic drugs (which stimulate muscarinic receptors) may reduce the effectiveness of one or both medications.
The concept of anticholinergic burden is particularly important. This refers to the cumulative effect of all anticholinergic medications a patient takes. High anticholinergic burden has been associated with cognitive decline, falls, delirium, and increased mortality in older adults. Before adding Solifenacin Orion to an existing medication regimen, a comprehensive medication review should be considered.
Major Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Ketoconazole | Antifungal (strong CYP3A4 inhibitor) | Strongly inhibits CYP3A4, significantly increasing solifenacin blood levels (up to 2–3 fold) | Remain on solifenacin 5 mg/day; contraindicated in severe renal or moderate hepatic impairment |
| Itraconazole | Antifungal (strong CYP3A4 inhibitor) | Strong CYP3A4 inhibitor that increases solifenacin exposure | Remain on solifenacin 5 mg/day; monitor for increased anticholinergic effects |
| Ritonavir / Nelfinavir | HIV protease inhibitors (strong CYP3A4 inhibitors) | Potent CYP3A4 inhibitors that significantly reduce solifenacin metabolism | Remain on solifenacin 5 mg/day; close clinical monitoring recommended |
| Clarithromycin / Erythromycin | Macrolide antibiotics (moderate-strong CYP3A4 inhibitors) | Increase solifenacin exposure and risk of anticholinergic effects | Monitor for dry mouth, constipation, blurred vision; dose adjustment rarely needed |
| Verapamil / Diltiazem | Calcium channel blockers (moderate CYP3A4 inhibitors) | Moderate CYP3A4 inhibition increases solifenacin levels; potential additive cardiac effects | Caution advised; remain on 5 mg/day |
| QT-prolonging drugs | Class III antiarrhythmics, certain antibiotics, antipsychotics | Additive risk of QT prolongation and arrhythmia | Use with caution in patients with known QT prolongation; ECG monitoring may be appropriate |
Moderate Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Rifampicin | Antibiotic (strong CYP3A4 inducer) | Accelerates solifenacin metabolism, reducing blood levels and potentially decreasing efficacy | Monitor OAB symptom control; alternative treatments may be considered |
| Phenytoin / Carbamazepine | Antiepileptics (CYP3A4 inducers) | Induce CYP3A4, increasing the rate of solifenacin breakdown | Monitor efficacy; alternative OAB treatments may be considered if response is inadequate |
| St John's wort (Hypericum perforatum) | Herbal antidepressant (CYP3A4 inducer) | May lower solifenacin blood levels and reduce its effectiveness | Avoid concomitant use; inform your doctor about all herbal supplements |
| Other anticholinergics | Various (e.g., first-generation antihistamines, tricyclic antidepressants, ipratropium, oxybutynin) | Additive anticholinergic effects: increased risk of dry mouth, constipation, urinary retention, cognitive impairment, and falls | Avoid combining multiple anticholinergics when possible; minimise anticholinergic burden, particularly in elderly patients |
| Metoclopramide / Cisapride | Prokinetic agents | Solifenacin may reduce the effectiveness of prokinetics by opposing their gut motility-enhancing action | Evaluate need for both medications; effects may be mutually antagonistic |
| Bisphosphonates | Osteoporosis medications (e.g., alendronate, risedronate) | Anticholinergics may worsen or contribute to oesophagitis when combined with bisphosphonates | Take bisphosphonates strictly as directed (remain upright, plenty of water); report swallowing difficulty or chest pain |
Food, Drink, and Grapefruit Interactions
Solifenacin Orion can be taken with or without food, according to your preference. Food does not significantly affect the absorption or bioavailability of solifenacin, meaning you do not need to time your dose around meals. There is some theoretical concern that grapefruit and grapefruit juice (which inhibit intestinal CYP3A4) could modestly increase solifenacin blood levels, but clinically significant effects at normal dietary intakes have not been demonstrated. If you regularly consume large amounts of grapefruit juice, mention this to your doctor.
Alcohol does not interact directly with solifenacin, but both can cause drowsiness and dizziness. Moderate alcohol intake is generally acceptable during solifenacin treatment, but it is wise to see how you respond before driving or engaging in activities requiring alertness. As with any OAB treatment, maintaining an adequate fluid intake is advisable; severe fluid restriction can concentrate urine and irritate the bladder, potentially worsening symptoms.
What Is the Correct Dosage of Solifenacin Orion?
The recommended dose of Solifenacin Orion is 5 mg once daily, taken as a whole film-coated tablet with liquid. The tablet should be swallowed whole and not crushed, broken, or chewed. Solifenacin Orion is only available in the 5 mg strength; if a higher dose is clinically indicated, your doctor will prescribe an alternative solifenacin product.
Always take Solifenacin Orion exactly as your doctor or pharmacist has told you. Do not change your dose without consulting your healthcare provider first. The effectiveness of solifenacin may take up to 4 weeks to be fully apparent, so it is important to continue taking the medication as prescribed even if you do not notice immediate improvement. Because of the long elimination half-life, steady-state plasma concentrations are typically reached after about 10–14 days of continuous daily dosing.
Adults
Standard Adult Dosage
Recommended dose: 5 mg once daily
Maximum dose: 5 mg once daily (for Solifenacin Orion, which is only available in 5 mg strength)
Administration: Swallow the tablet whole with a glass of water. Can be taken with or without food at any time of day, but preferably at the same time each day for consistent effect. Do not crush or split the tablet.
Dose escalation: If the 5 mg dose provides insufficient symptom relief after 4–6 weeks, your doctor may consider an alternative solifenacin product available in 10 mg strength or may switch you to a different anticholinergic or beta-3 agonist therapy.
Special Populations
Patients with Renal Impairment
Mild to moderate renal impairment: No dose adjustment required; the usual 5 mg daily dose is appropriate
Severe renal impairment (creatinine clearance < 30 mL/min): Maximum dose 5 mg daily; use with caution and monitor closely
Haemodialysis: Contraindicated – do not use Solifenacin Orion if you are on dialysis
Patients with Hepatic Impairment
Mild (Child-Pugh A): No dose adjustment required
Moderate (Child-Pugh B): Maximum dose 5 mg daily
Severe (Child-Pugh C): Contraindicated – do not use Solifenacin Orion
Patients Taking CYP3A4 Inhibitors
If you are also taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin), the solifenacin dose should not exceed 5 mg daily. Your doctor will have informed you if this applies. Because Solifenacin Orion is only available as 5 mg tablets, no dose reduction beyond the standard dose is typically required; however, you should not add a second tablet on the same day.
Children and Adolescents
Solifenacin Orion should not be used in children and adolescents under 18 years of age for the treatment of overactive bladder. There is insufficient evidence regarding its safety and efficacy in this age group for this indication, and paediatric urological conditions generally require specialist assessment and individualised treatment.
Elderly Patients
No specific dose adjustment is required solely based on age. The standard 5 mg daily dose of Solifenacin Orion is appropriate for most elderly patients. However, elderly patients may be more susceptible to anticholinergic side effects, including dry mouth, constipation, cognitive effects, and an increased risk of falls. International guidelines from the European Association of Urology (EAU) and the American Geriatrics Society (AGS) recommend that total anticholinergic burden be carefully assessed in elderly patients, particularly those with existing cognitive impairment, multiple comorbidities, or those already taking other anticholinergic medications. The 5 mg strength of Solifenacin Orion is well suited to elderly patients because it allows treatment to start at the lower, better-tolerated dose.
Missed Dose
If you forget to take a dose at your usual time, take it as soon as you remember on the same day, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten dose. Never take more than one tablet per day. If you frequently forget to take your doses, consider using a pillbox organiser, setting a daily phone alarm, or linking your dose to a routine event (such as brushing your teeth each morning) to improve adherence.
Overdose
If you have taken more Solifenacin Orion than you should, or if a child has accidentally swallowed any tablets, contact your doctor, hospital emergency department, or poison control centre immediately for risk assessment and advice. Bring the medication packaging with you so that healthcare professionals know exactly what has been taken.
Symptoms of solifenacin overdose typically reflect exaggerated anticholinergic effects and may include:
- Severe dry mouth
- Headache and dizziness
- Drowsiness and severely blurred vision
- Hallucinations (seeing or hearing things that are not there)
- Agitation and excitability
- Seizures (convulsions)
- Difficulty breathing
- Rapid heart rate (tachycardia) and irregular heart rhythm
- Urinary retention (inability to urinate)
- Dilated pupils (mydriasis)
- Hot, dry, flushed skin
Management of solifenacin overdose is supportive. There is no specific antidote. Gastric lavage may be considered if presentation is within one hour of ingestion. Activated charcoal may reduce absorption if given early. In severe cases, the anticholinesterase physostigmine has occasionally been used under specialist supervision, particularly for severe central anticholinergic effects, but this requires careful monitoring because it carries its own risks.
If someone has taken a large overdose of solifenacin and is experiencing severe symptoms such as difficulty breathing, seizures, or loss of consciousness, call emergency services immediately. Do not attempt to induce vomiting unless specifically instructed by a healthcare professional or poison control centre.
Stopping Treatment
If you stop taking Solifenacin Orion, your overactive bladder symptoms are likely to return or worsen, usually within days to weeks, because the medication only treats symptoms and does not cure the underlying condition. There is no need to taper the dose; solifenacin can be stopped abruptly without withdrawal effects. However, always consult your doctor before discontinuing treatment. Your doctor can discuss alternative management options if solifenacin is not providing adequate relief or if side effects are problematic, including:
- Other anticholinergic medications (e.g., tolterodine, darifenacin, fesoterodine, trospium)
- Beta-3 adrenergic receptor agonists (e.g., mirabegron, vibegron)
- Behavioural therapies (bladder training, fluid management, pelvic floor muscle exercises)
- Advanced therapies for refractory OAB (e.g., botulinum toxin A bladder injections, percutaneous tibial nerve stimulation, sacral neuromodulation)
What Are the Side Effects of Solifenacin Orion?
Like all medicines, Solifenacin Orion can cause side effects, although not everybody gets them. The most common side effect is dry mouth. If you experience a severe allergic reaction (such as swelling of the face, lips, or throat with difficulty breathing) or severe skin reactions (blistering or peeling), seek immediate medical attention.
Anticholinergic side effects are the most frequently reported adverse reactions with solifenacin and are generally dose-dependent. Most side effects are mild to moderate in severity and tend to diminish over time as your body adjusts to the medication. The following frequency grid summarises the known side effects based on clinical trial data and post-marketing surveillance, using standardised frequency categories as defined by the European Medicines Agency (EMA) Council for International Organizations of Medical Sciences (CIOMS).
Angioedema (allergic swelling of tissue beneath the skin) with airway obstruction (difficulty breathing) has been reported in some patients taking solifenacin. If angioedema occurs, treatment must be stopped immediately and appropriate emergency treatment initiated. Also seek immediate help for severe skin reactions such as blistering or widespread peeling of the skin (possible signs of Stevens-Johnson syndrome or erythema multiforme).
Very Common
- Dry mouth
Common
- Blurred vision
- Constipation
- Nausea
- Dyspepsia (indigestion with symptoms such as fullness, abdominal pain, belching, and heartburn)
- Abdominal discomfort
Uncommon
- Urinary tract infection, bladder infection
- Drowsiness (somnolence)
- Altered taste (dysgeusia)
- Dry or irritated eyes
- Dry nasal mucosa
- Gastro-oesophageal reflux disease
- Dry throat
- Dry skin
- Difficulty urinating
- Fatigue
- Lower limb oedema (swelling)
Rare
- Faecal impaction (large accumulation of hard stool in the colon)
- Urinary retention (inability to empty the bladder)
- Dizziness, headache
- Vomiting
- Itching (pruritus), skin rash
Very Rare and Post-Marketing Reports
The following side effects have been reported very rarely (up to 1 in 10,000 people) or during post-marketing surveillance where the frequency cannot be precisely determined:
- Psychiatric: Hallucinations, confusion, delirium, agitation
- Metabolic: Decreased appetite, elevated potassium levels (hyperkalaemia) which may lead to abnormal heart rhythm
- Eye: Increased intraocular pressure (glaucoma), angle-closure glaucoma
- Cardiac: Changes in heart electrical activity (ECG), QT prolongation, torsade de pointes, palpitations, tachycardia (rapid heart rate), atrial fibrillation
- Respiratory: Voice disorders (dysphonia)
- Hepatic: Liver disorders, elevated liver enzymes
- Musculoskeletal: Muscle weakness
- Renal: Kidney disorders
- Skin: Erythema multiforme, exfoliative dermatitis, allergic rash
Tips for Managing Common Side Effects
Many anticholinergic side effects can be managed with simple self-care measures. These practical tips often allow patients to continue successful treatment:
- Dry mouth: Sip water frequently, suck on sugar-free sweets or ice cubes, chew sugar-free gum, use saliva substitutes, and maintain good oral hygiene to reduce the risk of dental caries
- Constipation: Increase dietary fibre intake (fruit, vegetables, whole grains), drink plenty of fluids, engage in regular physical activity; laxatives may be considered on medical advice if lifestyle measures are insufficient
- Blurred vision: Usually mild and transient; avoid driving or operating machinery until resolved; consult an optometrist if symptoms persist
- Dry eyes: Over-the-counter artificial tears or lubricating eye drops can provide relief
- Heat intolerance: Anticholinergics can reduce sweating; take care in hot weather and increase fluid intake
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed above. You can also report side effects directly to your national medicines regulatory authority (for example, the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) MedWatch programme). By reporting side effects, you can help provide more information on the safety of this medicine and support continued pharmacovigilance.
How Should You Store Solifenacin Orion?
Solifenacin Orion does not require any special storage conditions. Store the tablets in their original packaging, out of sight and reach of children. Do not use after the expiry date stated on the packaging.
There are no special temperature or humidity requirements for storing Solifenacin Orion tablets. The medication is stable at normal room temperature found in most homes. Keep the tablets in their original blister packaging to protect them from light and moisture until you are ready to take a dose. Avoid storing the medication in the bathroom, where humidity can be high, or in the kitchen near a cooker, where temperatures may fluctuate.
Keep this medicine out of the sight and reach of children at all times. Store all medicines securely to prevent accidental ingestion, particularly by young children who may mistake tablets for sweets. A locked medicine cabinet or high shelf is recommended in households with small children. Accidental solifenacin ingestion by a child is a medical emergency because children are more susceptible to anticholinergic toxicity.
Do not use Solifenacin Orion after the expiry date which is printed on the blister and the carton after "EXP". The expiry date refers to the last day of that month. Do not use this medicine if the packaging is damaged, if the tablet appears discoloured or broken, or if there are any other visible signs of tampering. If you are uncertain whether your medication is still usable, consult your pharmacist.
Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. Most pharmacies in Europe, North America, and many other regions operate take-back schemes for expired or unused medications. These measures help to protect the environment and reduce the risk of environmental contamination from pharmaceutical products, which can enter waterways and affect aquatic ecosystems.
What Does Solifenacin Orion Contain?
Each Solifenacin Orion film-coated tablet contains 5 mg of solifenacin succinate (equivalent to approximately 3.8 mg of solifenacin base) as the active ingredient, together with a small number of pharmacologically inactive excipients that help to form the tablet and its coating.
Active Ingredient
The active substance is solifenacin succinate. Each film-coated tablet contains 5 mg of solifenacin succinate. The succinate salt form has been selected for its optimal bioavailability, chemical stability, and suitability for oral dosage forms. Solifenacin is a small-molecule drug (molecular weight approximately 481.6 g/mol as succinate) with the chemical name (1S,3'R)-quinuclidin-3'-yl 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate succinate.
Inactive Ingredients (Excipients)
In addition to the active ingredient, the tablet contains the following inactive ingredients (excipients), which are used to form the tablet core and the film coating:
- Tablet core: Lactose monohydrate, maize starch, hypromellose, magnesium stearate
- Film coating: Hypromellose, talc, titanium dioxide (E171), macrogol (polyethylene glycol), yellow iron oxide (E172) for colouration
Note that the exact composition of excipients may vary slightly between batches and over product lifecycle, in line with regulatory requirements. The definitive list for your specific pack can be found in the official patient information leaflet that accompanies the medication.
Tablet Appearance
Solifenacin Orion 5 mg tablets are film-coated tablets that are typically round, biconvex, and light yellow in colour. The tablets are debossed or imprinted with identifying markings that distinguish them from other tablet products. The exact physical appearance, markings, and size may vary slightly depending on the specific production batch and marketing region.
Pack Sizes
Solifenacin Orion is typically available in blister packs containing 10, 30, 50, 90, or 100 tablets, although not all pack sizes may be marketed in all countries. Pack sizes are selected to support different treatment durations, from short initial trials (30 tablets provides approximately one month of therapy) to longer-term supplies for established patients.
Marketing Authorisation Holder
Solifenacin Orion is manufactured and marketed by Orion Corporation, Orionintie 1, FI-02200 Espoo, Finland. Orion Corporation is a Nordic pharmaceutical company with global operations, specialising in both innovative and generic medicines. The company operates under the oversight of European and national regulatory authorities and manufactures its products in accordance with EU Good Manufacturing Practice (GMP) standards.
Therapeutic Equivalence
As a generic medicinal product, Solifenacin Orion has been demonstrated to be bioequivalent to the originator brand (Vesicare) and is therefore therapeutically interchangeable at the 5 mg dose strength. Bioequivalence means that the rate and extent of absorption of the active ingredient from Solifenacin Orion and from the reference product are comparable within accepted statistical limits. Patients can typically be switched between the originator and generic solifenacin products without clinical consequence, although any switch should always be discussed with a prescribing doctor.
Frequently Asked Questions About Solifenacin Orion
Solifenacin Orion is used to treat overactive bladder (OAB) symptoms in adults, including urinary urgency (a sudden, strong need to urinate), frequency (needing to urinate more often than normal), and urge incontinence (involuntary leakage of urine when you cannot reach the toilet in time). It works by relaxing the bladder muscle, allowing you to wait longer between bathroom visits and reducing episodes of urgency and incontinence. It is not suitable for children or adolescents under 18 years of age.
The most common side effect is dry mouth, affecting more than 1 in 10 users. Other common side effects include blurred vision, constipation, nausea, and indigestion. These anticholinergic side effects are generally mild to moderate and tend to improve over time as your body adjusts to the medication. Practical self-care measures such as sipping water, chewing sugar-free gum, and eating a high-fibre diet can help manage these effects.
You may notice some improvement in your symptoms within the first week, but it typically takes up to 4 weeks to experience the full therapeutic benefit of Solifenacin Orion. The medication has a long half-life of 45–68 hours, which means it takes about 10–14 days of daily dosing to reach steady-state levels in your body. Be patient and continue taking it as prescribed. If you see no meaningful improvement after 4–6 weeks, speak with your doctor about the next steps.
Yes, in terms of active ingredient and clinical effect. Solifenacin Orion is a generic version of solifenacin, while Vesicare is the original branded product developed by Astellas Pharma. Both contain the same active substance (solifenacin succinate) and have been demonstrated to be bioequivalent at the 5 mg dose, meaning they deliver the same amount of drug to the bloodstream at the same rate. Generic products like Solifenacin Orion are typically more affordable and are considered therapeutically interchangeable with the originator.
There is no specific interaction between solifenacin and alcohol. However, both solifenacin and alcohol can cause drowsiness and dizziness, so combining them may increase these effects, particularly at higher alcohol intakes. If you choose to drink alcohol, do so in moderation and see how the combination affects you before driving or operating machinery. Alcohol is also a bladder irritant and can increase urinary frequency, potentially counteracting the benefits of solifenacin.
Solifenacin Orion can be used in elderly patients, but special caution is warranted. Older adults are generally more sensitive to anticholinergic side effects, including dry mouth, constipation, urinary retention, drowsiness, potential cognitive effects, and an increased risk of falls. International guidelines recommend assessing the total anticholinergic burden in elderly patients and starting with the lowest effective dose. The 5 mg strength of Solifenacin Orion corresponds to this recommended starting dose, making it a suitable choice for older patients when appropriate.
Constipation is a common anticholinergic side effect. Mild constipation can often be managed with increased dietary fibre (fruits, vegetables, whole grains), adequate fluid intake, and regular physical activity. Over-the-counter laxatives (e.g., osmotic laxatives or stool softeners) may be used on pharmacist advice. If constipation becomes severe, persistent, or is accompanied by abdominal pain, bloating, vomiting, or blood in the stool, contact your doctor promptly. In rare cases, solifenacin can cause faecal impaction, which may require medical intervention. Your doctor may recommend dose modification or switching to an alternative treatment.
All anticholinergic medications carry a theoretical risk of cognitive effects, particularly in elderly patients. Solifenacin is relatively selective for the M3 muscarinic receptor and has limited penetration across the blood-brain barrier compared with some older anticholinergics (such as oxybutynin), which theoretically makes it less likely to cause central nervous system effects. However, rare cases of confusion, disorientation, and hallucinations have been reported with solifenacin, especially in older adults or those taking multiple anticholinergic medications. If you or a family member notices any cognitive changes while on Solifenacin Orion, contact your doctor promptly to discuss whether the medication should be continued or changed.
References
- European Medicines Agency (EMA). Solifenacin – Summary of Product Characteristics. Available at: www.ema.europa.eu.
- Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International. 2004;93(3):303–310. doi:10.1111/j.1464-410X.2004.04612.x
- Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology. 2004;172(5 Pt 1):1919–1924.
- European Association of Urology (EAU). Guidelines on the Management of Non-Neurogenic Female Lower Urinary Tract Symptoms (LUTS). 2023 Edition. Available at: uroweb.org/guidelines.
- American Urological Association (AUA) / Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU). Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment. 2019.
- Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourology and Urodynamics. 2002;21(2):167–178.
- Chapple CR, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. European Urology. 2005;48(1):5–26. doi:10.1016/j.eururo.2005.02.024
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list. 2023. Available at: www.who.int.
- National Institute for Health and Care Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women: management. NICE guideline [NG123]. 2019.
- Wagg A, Gibson W, Ostaszkiewicz J, et al. Urinary incontinence in frail elderly persons: Report from the 5th International Consultation on Incontinence. Neurourology and Urodynamics. 2015;34(5):398–406.
- British National Formulary (BNF). Solifenacin succinate. Joint Formulary Committee, BMJ Group and Pharmaceutical Press. Current edition.
- Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Internal Medicine. 2015;175(3):401–407. doi:10.1001/jamainternmed.2014.7663
Editorial Team
This article has been written and reviewed by our medical editorial team, consisting of licensed physicians with specialist expertise in urology, clinical pharmacology, and internal medicine. All drug information is based on the most recent Summary of Product Characteristics approved by the European Medicines Agency and corroborated with independent peer-reviewed literature.
iMedic Medical Editorial Team – specialists in urology, clinical pharmacology, and pharmaceutical science with documented clinical and research experience.
iMedic Medical Review Board – an independent panel of senior physicians who verify all content according to international guidelines (WHO, EAU, AUA, ICS, NICE).
All medical content on iMedic is based on evidence level 1A (systematic reviews and meta-analyses of randomised controlled trials) following the GRADE evidence framework. We have no commercial funding and accept no pharmaceutical sponsorship. Content is reviewed at least annually or when significant new evidence becomes available. Read more about our editorial standards.